Total Pharmacy |

The risk of drug shortages is increasing as the long-term sustainability of generic manufacturing faces challenges, including low return on investment because of lowered prices, drug purchasers becoming more concentrated, and new generics facing slow adoption.

The Equitable Community Access to Pharmacy Services legislation was introduced earlier this year in the House of Representatives.

Filling a prescription for a controlled substance requires more oversight than the average prescription.

Technology can bolster and optimize independent pharmacies’ delivery of clinical services.

Social media marketing is a powerful tool that pharmacists can use.

Employers must make changes in order to hire and retain high-quality talent.

The world continues to become more automated, but how much responsibility should you give AI within your pharmacy?

Issues within chain pharmacies have made the profession less attractive for new graduates.

What are pharmacies capable of, and how do we work to reach those possibilities?

Only 1 in 5 patients who initiated buprenorphine were retained in therapy for at least 180 days.

Artificial intelligence can be a key tool for streamlining pharmacy workflows.

Over the last 5 years, both PBMs and drug manufacturers have implemented restrictions that raise patients’ cost burden for specialty medications.

Filling prescriptions is no longer a sufficient source of revenue for community pharmacy.

NCPA, NACDS, and APhA have joined the Healthcare Distribution Alliance in calling for a delay in the implementation of DSCSA.

The Drug Supply Chain Security Act has been a decade in the making. Pharmacists must be prepared to comply by November 2023.

Customers expect high-quality customer service. Technology can help pharmacists meet those expectations.

A Q&A with Colin Banas, MD, chief medical officer at health care software company DrFirst.

Pharmacists can utilize AI for medication management and to prevent medication errors.

Vaccination can minimize health care costs associated with influenza.

The Humira biosimilar is a tumor necrosis factor (TNF) blocker and was approved by the FDA in 2021.

Employing AI-driven technology ensures accurate and timely compliance with industry regulations, mitigates audits and fines, and helps forecast accurate reimbursements.

The company has been working since 2015 to implement the track and trace elements required by the Drug Supply Chain Security Act.